Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s stock price reached a new 52-week low on Thursday. The stock traded as low as GBX 32 and last traded at GBX 32.50, with a volume of 27,079 shares. The stock had previously closed at GBX 36.
Faron Pharmaceuticals Oy Price Performance
The company has a 50 day moving average price of GBX 36.71 and a 200-day moving average price of GBX 40.68. The company has a quick ratio of 1.09, a current ratio of 2.40 and a debt-to-equity ratio of 154.15. The company has a market cap of £64.96 million, a price-to-earnings ratio of -2.78 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
